Sho Kubota

Affiliation and department：

Research field (3)： Pharmacology , Pharmaceuticals - health and biochemistry , Hematology and oncology

Research keywords (10)： NO , BPDCN , 造血幹細胞 , バイオインフォマティクス , 転写因子 , 細胞内シグナル伝達 , チロシンキナーゼ , 環境化学物質 , 白血病 , エピジェネティクス

Research theme for competitive and other funds (11)：

2024 - 2028 Integrated understanding of the mechanisms of maintenance and breakdown of epigenomic resilience for health
2021 - 2024 MLL融合白血病発症を受容する胎児造血幹細胞形質の解析
2018 - 2021 Leukemic development through chromosomal translocation with super-enhancer exchange
2017 - 2020 Epigenome abnormality in leukemic stem cells
2015 - 2018 Roles of tyrosine phosphorylation of KAP1 in leukemogenesis

Show all

Papers (42)：

Haruna Kurogi, Nobumasa Takasugi, Sho Kubota, Ashutosh Kumar, Takehiro Suzuki, Naoshi Dohmae, Daisuke Sawada, Kam Y J Zhang, Takashi Uehara. Discovery of a Compound That Inhibits IRE1α S-Nitrosylation and Preserves the Endoplasmic Reticulum Stress Response under Nitrosative Stress. ACS chemical biology. 2024
Ryohei Miki, Ryosuke Nomura, Yuta Iijima, Sho Kubota, Nobumasa Takasugi, Takao Iwawaki, Masatake Fujimura, Takashi Uehara. Therapeutic potential of 4-phenylbutyric acid against methylmercury-induced neuronal cell death in mice. Archives of toxicology. 2024
Sho Kubota, Yuqi Sun, Mariko Morii, Jie Bai, Takako Ideue, Mayumi Hirayama, Supannika Sorin, Eerdunduleng, Takako Yokomizo-Nakano, Motomi Osato, et al. Chromatin modifier Hmga2 promotes adult hematopoietic stem cell function and blood regeneration in stress conditions. The EMBO Journal. 2024
Mariko Morii, Sho Kubota, Mihoko Iimori, Takako Yokomizo-Nakano, Ai Hamashima, Jie Bai, Akiho Nishimura, Masayoshi Tasaki, Yukio Ando, Kimi Araki, et al. TIF1β activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia. Leukemia. 2024
Hiroto Ohguchi, Yasuyo Ohguchi, Sho Kubota, Kan Etoh, Ai Hamashima, Shingo Usuki, Takako Yokomizo-Nakano, Jie Bai, Takeshi Masuda, Yawara Kawano, et al. Multiple myeloma-associated DIS3 gene is essential for hematopoiesis but loss of DIS3 is insufficient for myelomagenesis. Blood Neoplasia. 2024. 100005-100005

ｍore...

MISC (4)：

指田吾郎, 横溝貴子, 久保田翔, 原田浩徳, 大里元美, 岩間厚志. Tet2欠損によるHmga2機能制御と骨髄異形成症候群発症の分子基盤(Tet2 loss reshapes Hmga2 binding regions to promote the development of myelodysplastic syndrome). 日本癌学会総会記事. 2019. 78回. E-2077
横溝貴子, 久保田翔, 岩間厚志, 原田浩徳, 大里元美, 指田吾郎. RUNX3発現による骨髄異形成症候群発症の分子基盤解明(RUNX3 over-expression impedes RUNX1 function and promotes the development of myelodysplastic syndrome). 日本癌学会総会記事. 2019. 78回. P-2224
Sho Kubota, Kenji Tokunaga, Tomohiro Umezu, Takako Yokomizo, Motohiko Oshima, Eisaku Iwanaga, Norio Asou, Atsushi Iwama, Kazuma Ohyashiki, Motomi Osato, et al. Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm. BLOOD (International Conference). 2018. 132
久保田翔, 梅津知宏, 岩間厚志, 大屋敷一馬, 大里元美, 指田吾郎. RUNX2スーパーエンハンサーによるMYCの活性化を介したBPDCNの発症メカニズムの解析(Lineage-specific RUNX2 super-enhancer activates MYC via a chromosomal translocation and promotes the BPDCN). 日本癌学会総会記事. 2018. 77回. 1966-1966

Education (3)：

Professional career (1)：

Work history (4)：

Committee career (3)：

Awards (5)：

Association Membership(s) (4)：

日本薬理学会 , 日本毒性学会 , 日本血液学会 , 日本薬学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page